

Medtronic strengthens its extensive body of real-world evidence on its MiniMed™ 780G system with new presentations at the American Diabetes Association 84th Scientific Sessions

Medtronic, a global leader in medical technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) 84th Scientific Sessions. Following the one-year anniversary of the MiniMed™ 780G system approval and launch in the U.S., Medtronic Diabetes continues to demonstrate its success with consistently strong real-world evidence – particularly around its unique ability to manage hyperglycemia across diverse populations of individuals with type 1 diabetes. Hyperglycemia continues to be an unmet need and Medtronic Diabetes is committed to ensuring tight management to prevent the devastating short- and long-term complications associated with prolonged highs. The growing body of evidence not only demonstrates strong clinical outcomes, but reduced burden for people living with diabetes, and overall satisfaction in the experience it's delivering.

In addition to its latest data, the company will also showcase an enhanced CareLink™ experience for healthcare professionals – the first of many steps towards revolutionizing the Medtronic digital ecosystem for both patients and HCPs. Launching globally in early June, the new CareLink™ experience features a new patient dashboard and a quick view of the metric that matters most: Time in Range. A new dedicated Time in Range column will provide a snapshot of how all of the patients in their care are doing so they can quickly identify those in need of extra support. The updated CareLink™ system will be on display throughout the congress at the Medtronic Diabetes booth and demonstrated via an in-booth presentation.

The Medtronic booth will also showcase its CE-marked Simplera Sync™ sensor with the MiniMed™ 780G system, which will begin its phased commercial launch in Europe in late July. (CAUTION: Investigational, not approved for commercial use in the US). The Simplera Sync™ is a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors with the MiniMed™ 780G system, Medtronic's most advanced insulin delivery system. It was unveiled earlier this year via a limited release in preparation for commercial availability in Europe.

The following symposia will feature discussions with Medtronic and independent speakers. Details are as follows:

titled "How soon should AID be offered? Success in typically hard to manage populations with the MiniMed™ 780G system" chaired by Jennifer McVean, MD, Sr. Medical Director, Medtronic Diabetes, on Saturday, June 22, 12:30-1:30 p.m. ET featuring the below experts:

	<i>Richard Bergenstal, MD</i>
	<i>Gregory Forlenza, MD Barbara Davis Center</i>
	<i>Laya Ekhlaspour, MD UCSF</i>
	<i>Ben Wheeler, MD, PhD University of Otago</i>

titled "The MiniMed™ 780G system algorithm explained" by Lou Lintereur, Sr. Distinguished Engineer, Medtronic Diabetes, on Sunday, June 23 at 11:00-11:20 a.m. ET.

featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for

HCPs and patients, including a showcase of the enhanced CareLink™ system with updated features for HCPs.

In Booth presentations will include:

- "CareLink™ for the MiniMed™ 780G system is as easy as 1-2-3" by Jennifer McVean, MD, Medical Director, Medtronic Diabetes, on Saturday June 22 1:45-2:05 p.m. ET.
- "Lightening the Load: How the Medtronic Extended™ infusion set is alleviating patient burden" by Sarnath Chattaraj, PhD, Sr. Research Director, Consumables R&D, Medtronic Diabetes, on Sunday June 23 at 1:00-1:20 p.m. ET.

The following poster presentations showcase the work of Medtronic employees and independent investigators using Medtronic devices in their research. Posters will be on display in the Poster Hall and attendees can view them throughout the conference.

- "Safety and Glycemic Outcomes of Adults with Type 2 Diabetes* (T2D) in a MiniMed™ Advanced Hybrid Closed-Loop (AHCL) System Trial" – poster (945-P) by Anuj Bhargava, MD, endocrinologist, Iowa Diabetes Research, on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Significant Reduction in Real-World Nighttime Burden with the MiniMed™ 780G System (MM780G)" – poster (961-P) by John Shin, PhD, Sr. Director of Clinical Research, Medtronic Diabetes, on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Hyperglycemia from Real-World Dawn Phenomenon is Nearly Eliminated with the MiniMed™ 780G System (MM780G)" – poster (972-P) by Jennifer McVean, MD, Sr. Medical Director, Medtronic Diabetes on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Cost-effectiveness of the MiniMed™ 780G system compared to multiple daily injections (MDI) used with the Dexcom™ G6 continuous glucose monitoring (CGM) system" – poster (1056-P) by Mallika Kommareddi, MPH, Principal Health Economics & Outcomes Research Specialist, Medtronic Diabetes, on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Retrospective Medtronic CGM-Driven Missed Meal Bolus Detection Tool" – poster (947-P) by Andrea Benedetti, Sr. Scientist, Medtronic Diabetes, on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Safety glycemic outcomes using the MiniMed™ 780G system with a disposable all-in-one sensor with transmitter (1901 LB)" – late-breaking poster by Gregory Forlenza, MD, pediatric endocrinologist, Barbara Davis Center, on Saturday, June 22, 12:30-1:30 p.m. ET.
- "Present and future: the MiniMed™ 780G system poster tour" by Robert Vigersky, MD, CMO, Medtronic Diabetes, on Sunday, June 23, at 1:30-2:00 p.m. ET

www.medtronicdiabetes.com

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

* CareLink is a class I exempt product in the US and has self-certified CE-marking in the EU.

**The MiniMed™ 780G system has not been approved for use in type 2 diabetes by FDA or other regulatory bodies.

+1 (818) 576-3025

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626

https://stage.mediaroom.com/minimed_mr/2024-06-03-Medtronic-strengthens-its-extensive-body-of-real-world-evidence-on-its-MiniMed-TM-780G-system-with-new-presentations-at-the-American-Diabetes-Association-84th-Scientific-Sessions